Ana Belo,  —

Potential Gene Therapy for Dystrophic EB, KB103, Named an Orphan Drug by FDA

A potential gene therapy for dystrophic epidermolysis bullosa (DEB), KB103 by Krystal Biotech, has been designed an Orphan Drug by the U.S. Food & Drug Administration (FDA) to help it move along in preclinical testing. KB103 is the company’s lead candidate, and is intended to treat…

BERG Receives Partners in Progress Award for Efforts in Treating Epidermolysis Bullosa

The biopharmaceutical company BERG was honored with a Partners in Progress Award from the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America). The award recognized BERG’s efforts in developing new therapeutic strategies for epidermolysis bullosa (EB). “We’re honored to be recognized by debra…